through metabolic oligosaccharide engineering. [ 1, 2 ] This technique exploits the substrate promiscuity of cellular biosynthetic enzymes to deliver unnatural monosaccharides bearing bioorthogonal functional groups into cellular glycans.
For example, derivatives of Nacetylmannosamine (ManNAc) are converted by the cellular biosynthetic machinery into the corresponding sialic acids and subsequently delivered to the cell surface in the form of sialoglycoconjugates ( Figure  1A ). Analogs of N-acetylglucosamine (GlcNAc) and Nacetylgalactosamine (GalNAc) are also metabolized and incorporated into cell surface glycans, likely through the sialic acid and GalNAc salvage pathways, respectively. [3] [4] [5] [6] Furthermore, GlcNAc analogs can be incorporated into nucleocytoplasmic proteins in place of β-O-GlcNAc residues. [ 7 ] These pathways have been exploited to integrate unique electrophiles such as ketones and azides into the target glycoconjugate class. These functional groups can be further elaborated in a chemoselective fashion by condensation with hydrazides [ 8 ] and by Staudinger ligation [ 9 ] , respectively, thereby introducing detectable probes onto the cell (shown schematically in Figure 1B ).
We have previously demonstrated that N-levulinoylmannosamine (ManLev, 1a, Scheme 1) is metabolized by cells to N-levulinoyl sialic acid (SiaLev) (2a), which is then appended to glycoconjugates that are ultimately expressed on the cell surface. [ 3, 8 ] Increasing the length or steric bulk of the N-acyl side chain of 1a abrogates cell surface expression of the corresponding sialic acids. [ 10 ] A ratedetermining step in the de novo biosynthesis of unnatural sialic acids appears to be the phosphorylation of ManNAc at the 6-OH by ManNAc 6-kinase ( Figure 1A ). [ 10 ] Accordingly, Reutter and coworkers were able to introduce a broader spectrum of sialic acid analogs into cellular glycans by feeding cells the sialic acid derivative directly, thereby bypassing the bottleneck enzyme ( Figure 1A ). [ 11 ] These observations suggest that sialic acid analogs may be more efficient delivery vehicles for bioorthogonal functional groups than their mannosamine precursors.
To this end, we synthesized a series of sialic acid derivatives and evaluated the efficiency of their metabolism to cell surface sialosides. In most cases, the sialic acids were superior to the corresponding mannosamines. These analogs also permitted cell surface expression of novel groups that would not be tolerated by the de novo pathway, including an aryl azide with potential photocrosslinking capability.
We synthesized a panel of sialic acids bearing ketone side chains of various length at the N-acyl position, a site known to be tolerant of unnatural modifications in the context of the mannosamine precursor (i.e. ManLev, 1a).
Sialic acid analogs 2a-c (Scheme 1)
were synthesized by the neuraminic acid (NeuAc) aldolase-catalyzed condensation [ 12 ] of pyruvate and the corresponding mannosamine derivatives [ 10 ] (1a-c, Scheme 1).
Compounds 1a-c and 2a-c were incubated with the human T cell lymphoma Jurkat for three days to evaluate their metabolic incorporation into cell surface glycans.
Subsequent treatment of the cells with biotin hydrazide followed by FITC-avidin allowed analysis of cell surface ketone expression by flow cytometry. [ 3 ] As depicted in Figure 2 , keto sialic acids produced a higher level of cell surface ketones than the corresponding keto mannosamine analogs. The most significant difference was observed with the levulinoyl analogs 2a and 1a; the sialic acid analog produced 3-fold more cell surface ketones than the mannosamine analog.
The metabolic efficiency of longer side chain analogs was reduced in both the mannosamine and sialic acid series, but 5-oxohexanoyl analog 2b was integrated into cell surface glycans at significant levels, unlike its mannosamine congener. Even the further extended homolog 2c was expressed on the cell surface at levels significantly above background.
We next synthesized azide-containing sialic acid derivative 2d
for direct comparison with its previously studied mannosamine counterpart 1d [ 9 ] (Scheme 1). Compounds 2d and 1d were incubated with Jurkat cells and subsequently labeled with a phosphine reagent conjugated to the FLAG peptide (phosphine-FLAG). [ 4 ] Treatment of cells with a FITC-labeled anti-FLAG antibody enabled analysis of cell surface azide expression by flow cytometry. In contrast to the trend observed with the ketone derivatives, compounds 1d and 2d showed similar metabolic efficiency ( Figure  3A) . In this case, phosphorylation by ManNAc 6-kinase may not impede conversion of 1d to 2d, and a more downstream step may be rate-limiting. Notably, previous work has shown that compound 1d is processed by sialoside biosynthetic enzymes more efficiently than ManLev (1a) [ 4 ] , a result that might reflect a more efficient phosphorylation step for 1d.
Having demonstrated that larger acyl substituents can be escorted to the cell surface by sialic acid precursors, we sought to extend metabolic oligosaccharide engineering to novel functionalities such as photocrosslinkers. Thus, aryl azide analogs 1e and 2e were synthesized (Scheme 1) and subsequently incubated with Jurkat cells for three days. The cells were reacted with phosphine-FLAG, treated with the FITC-labeled anti-FLAG antibody and analyzed by flow cytometry ( Figure 3A previously demonstrated that the methyl ester of sialic acid is metabolized similarly to the free form, suggesting that the ester is cleaved inside cells. [ 11 ] To further improve the metabolic efficiency of our analogs, we investigated protected derivatives. Compound 2d was protected as its methyl ester (4d) and this derivative was tested for incorporation into cell surface glycans. As shown in Figure 3A , compound 4d was converted to the cell surface sialoside with the same efficiency as compound 2d. We further protected the hydroxyl groups to provide 
